Pipeline

We’re developing a pipeline of firsts.

Target
Candidate
Research
Preclinical
Phase 1
Phase 2
Phase 3
Alector’s Commercial Ownership
Partner
TREM2
Global 50-50 profit share with partner opt-in
abbvie logo

Program

Target

TREM2

Candidate

Phase 2b

Indication

Alzheimer's disease

Alector’s Commercial Ownership

Global 50-50 profit share with partner opt-in

Partner

abbvie logo

Close

AL001

Target

Progranulin

Indication

Frontotemporal dementia (FTD) in granulin mutation

Development Stage

Phase 3

AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.

AL001 is being developed in collaboration with GSK.

Close

AL101

Target

Progranulin

Indication

Neurodegenerative diseases

Development Stage

Phase 2

AL101 is designed to increase progranulin levels for the treatment of more prevalent neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.

AL101 is currently being studied in a Phase 1 clinical trial of healthy volunteers designed to assess safety, tolerability and pharmacokinetics and pharmacodynamics. AL101 is being developed in collaboration with GSK.

Close

AL002

Target

TREM2

Indication

Alzheimer’s disease

Development Stage

Phase 2b

Research suggests that reduction of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) functionality may lead to Alzheimer’s disease and other forms of dementia. AL002 is intended to counteract this decreased functionality by improving TREM2 signaling to enhance microglia activity.

The randomized, controlled Phase 2 study, INVOKE-2, in patients with early Alzheimer’s disease, will enroll approximately 265 participants and assess

AL002’s impact on disease progression, as well as changes in multiple fluid and imaging biomarkers. AL002 is being developed in collaboration with AbbVie.

Close